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1. Introduction 
1.1 Background 
Protein immunoassays provide information about quantities and forms of endogenous 
proteins. Uniplex enzyme immunoassays like Elisa have been the workhorse for protein 
measurement for decades, but they can be laborious and expensive and consume relatively 
large amounts of specimen. In comparison to the ELISA for a single analyte, multiplex 
assays offer the possibility of obtaining more reliable quantitative information in a highly 
parallel analysis. In addition, quantitative multiplexed assays offer the possibility to identify 
combinations of biomarkers with higher disease specificity than any single established 
biomarker alone. Because of these reasons, currently one-analysis, many-metabolites, many-
diseases approach is receiving more attention than uniplex system with one-analysis, one-
metabolite, one-disease.  
1.2 Multiplex immunoassay platforms 
Presently, antibody-based platforms are the core technology for protein multiplex arrays. 
Assay formats include suspension arrays (microbead assays) and planar arrays that use 
traditional immunometric principles.  
Planar arrays: MULTI-ARRAY (Meso Scale Discovery), A2 (Beckman Coulter), and FAST 
Quant (Whatman Schleicher & Schuell BioScience), Searchlight (Aushon Biosystem). 
Suspension arrays: Bio-Plex (Bio-Rad Laboratories), FlowCytomix (Bender MedSystems), 
cytometric bead array (Becton, Dickinson and Company) and the partners of Luminex Corp 
(XMAP)]. 
In the first format, different capture antibodies are spotted at defined positions on a 2-
dimensional array. In the second, the capture antibodies are conjugated to different 
populations of microbeads, which can be distinguished by their fluorescence intensity in a 
flow cytometer.  
Optimal assay performance of multiplex immunoassay platforms depend on proprietary 
information about the antibody pair, the composition of diluents, and the software. The 
accuracy of quantification for multiplexed immunoassays depends, as with all ELISAs, on 
the quality of the calibration curves, assay imprecision (CV), recoveries, and assay linearity 
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(the limits of quantification). Therefore, there is not a single assay platform suitable for all 
analytes. The selection of a platform or kit should depend on assay sensitivity, the relevant 
biological concentration to be measured 
 
Platform MesoScale discovery 
(MULTI-
ARRAY/MULTI-SPOT) 
Searchlight FastQuant 
(FAST Quant System) 
Capture antibody 
binding surface 
Carbon Plastic Nitrocellulose 
Detection system Electrochemiluminescent Biotinylated 
detector with 
fluorescent 
detection 
Biotinylated detector 
with fluorescent 
detection 
Analytes/plex Up to 10 Up to 24 Up to 10 
Image System CCD camera based CCD camera 
based 
CCD camera based 
Customised array Yes Yes Yes 
Kits for designing 
and building 
your own assay  
Yes No No 
Reagent company Waterman Scleicher& 
Schuell Bioscience  
Aushon 
Biosystem 
Waterman Scleicher& 
Schuell Bioscience 
Commercial 
instrument 
Waterman Scleicher& 
Schuell Bioscience 
Aushon 
Biosystem 
Waterman Scleicher& 
Schuell Bioscience 
Table 1. The characteristics of some commercial planar microspot array platforms 
 
Platform Luminex Cytometric Bead Array (CBA) 
Capture antibody 
binding surface 
Fluorescently tagged beads Fluorescently labeled beads 
Detection system Biotinylated detector with 
fluorescent detection 
Phycoerythrin conjugated 
detectors 
Analytes/plex Up to 100 Up to 100 
Image System Luminex XMAP based system Flow cytometer with dual laser 
Customised array Yes Yes 
Kits for designing 
and building your 
own assay  
Yes Yes 
Reagent company Luminex Corp and its 
partners(many others) 
BD Becton,Dickinson and others 
Commercial 
instrument 
Lumine(XMAP) and its partners BD Becton,Dickinson and others 
Table 2. The characteristics of some commercial suspension bead array platforms 
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Fig. 1. Process of multiplexed immunodetection using fluorescent-coded beads 
(www.millipore.com) 
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2. Bead based multiplex 
2.1 Background 
In multiplex bead array assays (MBAA), beads of discrete fluorescence intensities and 
wavelengths provide a capture surface for specific analytes enabling detection of multiple 
analytes in a single sample. Bead based assays of analyte is an attractive strategy for 
obtaining large numbers of measurements rapidly. MBAA is an open access system; namely, 
the parameters to be measured can be determined by the user. The variety of source 
increases its area of application (nucleic acids, antigens, antibodies, receptors).Since the 
detection method is based on flow cytometry and this allows repeatability, MBAA performs 
the quality control of the measurement, simultaneously with the measurement itself.  
The MBAA readers allow analysis of up to 100 reactions or assays per well. This remarkable 
capability allows incorporating a large number of assays, such as DNA, receptor-ligand, 
Immunoassay and enzyme in life science research, drug discovery as well as diagnostic areas. 
2.2 The principle of measurement 
These systems depend on measurement of fractional antibody occupancy using two different 
labels: one labeling the “capture” antibody, the second labeling a “detection antibody”, 
selected to react either with occupied or unoccupied sites on the “capture” antibody. The ratio 
of signals emitted by the two labeled antibodies reveals the analyte concentration to which the 
capture antibody has been exposed. An array of capture antibodies, each labeled with the 
same fluorescent label, is scanned (by a laser), and the fluorescent signal ratio emitted from 
each discrete antibody couplet in the array is measured.  
2.3 Summary of principles 
1. Color-coded beads, pre-coated with analyte-specific capture antibody for the molecule 
of interest are added. 
2. Analyte-specific antibodies capture the analyte of interest. Biotinylated detection 
antibodies specific to the analyte of interest are added and form an antibody-antigen 
sandwich. 
3. Phycoerythrin (PE)-conjugated Streptavidin is added. 
4. The beads are read by a dual-laser flow-based detection instrument which excites the 
internal dyes marking the beads set and a second laser excites PE, the fluorescent dye 
on the reporter molecule (www.luminexcorp.com). 
The system is capable of measuring potentially up to 100 analytes simultaneously in a small 
sample volume (25–50 µL). 
2.4 Advantages of the system 
1. Speed/High Throughput — Because each microsphere serves as an individual test, a 
large number of different assays can be performed and analyzed simultaneously 
2. Versatility — Bead based multiplex system can perform assays in several different 
formats, including nucleic acids and antigen-antibody binding, along with enzyme, 
receptor-ligand and other protein interactions 
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3. Flexibility — The technology can be customized for the user’s specific needs based 
upon their analytes of interest 
4. Accuracy — The technology generates real-time analysis and accurate quantification of 
the biological interactions (www.luminexcorp.com). 
Advantages of this approach also include specimen conservation, limited sample handling, 
and decreased time and cost. However, it is difficult to optimize assay format for each protein, 
to select common dilution factors and to establish reliable quality control algorithms. 
 
Characteristics Antibody-based 
Principle Antibody–antigen interaction 
Required reagents/information Specific antibody pairs 
Quantification basis flowcytometer and others 
Multiplexicity 1–100 
Clinical diagnostic test Yes 
Sample enrichment No 
Sensitivity >sub ng/mL–pg/mL 
Reproducibility Excellent 
Assay development Time and resource demanding 
Consumable High demand 
Robustness Yes 
Throughput High 
Matrix effect Yes 
Sample manipulation No 
Automation Yes 
History >15 years 
Table 3.The characteristics of MBAA 
2.5 Comparison with other technologies and assays 
The assay which is most often compared to MBAA is the enzyme-linked immunosorbent 
assay (ELISA). ELISAs, in general, use a similar immobilized antibody to capture a soluble 
ligand, with subsequent detection of the captured ligand by a second antibody. There are, 
however, several substantial differences between MBAA and ELISAs. For example, MBAA 
uses fluorescence as a detection system where ELISAs use enzyme amplification of a 
colorimetric substrate. MBAA captures ligands onto spherical beads in suspension while 
ELISAs generally rely upon flat surfaces in 96-well plates. Most importantly, MBAA 
techniques, by their very nature, are multiplexed and therefore may be subject to any 
perturbations that arise from analyzing multiple ligands simultaneously, such as cross-
reactivities. By contrast, ELISA methodologies generally study one analyte at a time, and 
thus avoid any concerns arising from multiplexing. 
Multiplex system presents additional Quality control (QC) challenges compared to uniplex 
analyses. The failure of 1 constituent assay to meet QC specifications results in rejection of 
results for all assays on the panel. Samples failing QC specifications should be retested using 
the same measurement system, because substitution of a uniplex assay may introduce bias 
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due to differences in assay format. However, the probability of all assays simultaneously 
meeting QC specifications is much lower than the probability of a uniplex test passing QC. 
At present, reference guidelines for multiplex QC programs are under development by the 
Food and Drug Administration (FDA).  
In theory, the MBAA platform may also provide a wider dynamic range than conventional 
ELISA methods because of the greater linear range of fluorescence intensity compared with 
absorbance. Detection limits of MBAA (luminex) and ELISA are different. A comparison of 
detection limits of some test for the Luminex assays and the ELISAs is shown in Table 4. Data 
Supplement (available at http://www.clinchem.org/content/vol51/issue7/) Disadvantage of 
MBAA are time consuming in assay development, lacking antibody pairs for new biomarkers 
and limited commercial multiplex assay kits. 
 
Multiplex panels  Analytes Luminex ELISA ELISA 
manufacturer 
Linco Endocrine Leptin 0.13 µg/L 1.39 µg/L Linco 
 Insulin  0.31 mIU/L 0.14 mIU/L Alpco 
 C-peptide 0.037 µg/L 0.132 µg/L Linco 
Biosource Chemokine MCP-1 2.35 ng/L 2.57 ng/L R&D 
 Eotaxin 4.37 ng/L 3.80 ng/L R&D 
Upstate Chemokine MCP-1 20.5 ng/L 2.57 ng/L R&D 
 Eotaxin 27.72 Eotaxin 3.80 ng/L R&D 
Linco Cytokine TNF-α 1.61 ng/L 0.092 ng/L R&D 
 IL-8 2.52 ng/L 0.26 ng/L Biosource 
Upstate Cytokine TNF-α 0.065 ng/L 0.092 ng/L R&D 
 IL-8 0.70 ng/L 0.26 ng/L Biosource 
 IL-6 0.75 ng/L 0.068 ng/L R&D 
R&D Cytokine TNF-α 1.53 ng/L 0.092 ng/L R&D 
 IL-6 0.977 ng/L 0.068 ng/L R&D 
Table 4. Comparison of detection limits for the Luminex multiplexed assays and the 
individual ELISAs. 
Protein microarray kits, which use capture antibodies and detection antibodies in a 
multiplex fashion similar to MBAA, should also be considered as a competing technology 
which is most commonly used for simultaneous determination of multiple proteins in a 
biological fluid. The technique uses primary antibodies as the immobilized probe on a solid 
surface, and protein antigens labeled with fluorophores with or without bound secondary 
antibodies are recognized and detected. However, binding of antibodies and antigens to a 
solid support can cause denaturation or drying of proteins. MBAA provides multiplexing in 
a solution phase and thus is particularly flexible and nondestructive for protein analysis. 
Also protein microarray assay are relatively new, are not widely accepted as a ‘gold 
standard’ for clinical use, and also may be of limited sensitivity. 
2.6 Areas of application 
Since a disease can result from various reasons and it may include functional disorders of 
multiple genes, a multi analyte analysis is necessary for diagnostic purposes. The 
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technology called omic and multiplex system allows a fast and systematic detection of the 
effects of micro molecules in different molecular and cellular contexts. In this respect, it can 
be used for diagnosing multi-reason/multi-gene diseases, performing a comprehensive 
disease management and investigating complex cellular functions. In addition, it provides a 
wide range of application area for research area because of its plasticity which allows the 
researchers to perform various studies.  
2.7 Clinical utility 
Despite the introduction of hundreds of multiplexed protein immunoassays to the research 
market in recent years, only a limited number have been cleared by the FDA for clinical use, 
an observation that illustrates the complexity of constructing robust arrays. Antibody-based 
multiplexed assay (and commercial instruments and kits) have a relatively long history with 
over 15 years of development and optimization. However, most commercial multiplex 
assays are developed for research laboratories and nonclinical tests; only a limited number 
of multiplex assays are approved by FDA for clinical testing. For example FDA-cleared 
planar protein multiplex arrays consist primarily of the lateral flow immunoassays used for 
point-ofcare evaluation . For example, the Triage® Cardio ProfilER® 4-plex measures 
troponin-I, creatine kinase-MB, myoglobin, and brain natriuretic peptide (BNP) to assist 
with evaluation of chest pain using a portable lateral flow platform. At present, suspension 
immunoassay is the prevailing technology for FDA-cleared multiplex protein 
measurements, especially for testing antibodies in the serum of patients with allergies or 
autoimmune or infectious diseases in clinical laboratories. 
 The other platforms for commercial multiplex diagnostic tests include Luminex 
(www.luminex.com), Triage system (www.Biosite.com), Evidence (www.Randox.com), 
Vidas (www.biomerieux-diagnostics. com), Planner arrays (www.VBC-genomics),Whatman 
(www.whatman.com) and bead array (www.bioarrays.com). At present, suspension 
immunoassay is the prevailing technology for FDA-cleared multiplex protein 
measurements, especially for testing antibodies in the serum of patients with allergies or 
autoimmune or infectious diseases in clinical laboratories. Most of the currently available 
multiplex immunoassays have been designed to quantify the concentrations of various 
cytokines.The recent development of spectrally-distinguishable fluorescent beads(Luminex) 
(Kellar and Iannone, 2002) has resulted in the widespread use of antigen-coupled beads for 
monitoring antibodies in sera by flow cytometry. These bead arrays have been adapted for 
serologic screening of antigens and have been described for up to ten antigens for HIV (Opalka 
et al., 2004), HPV (Opalka et al., 2003; Dias et al., 2005), Epstein-Barr virus (Klutts et al., 2004; 
Binnicker et al., 2008; Gu et al., 2008), B. anthracis (Biagini et al., 2004; Biagini et al., 2005), 
Influenza (Drummond et al., 2008) and M.tuberculosis (Khan et al.,2008). 
The results from a growing number of research studies, demonstrate that multiplex 
technology may be useful in clinical research to measure a large number of analytes to 
examine the association with a clinical phenotype and the effects of therapeutic 
interventions, and that this technology may be particularly useful when sample volume is 
limited, such as in large epidemiologic studies and clinical trials. Clinical applications must 
follow establishment of globally accepted calibration standards, performance criteria, and 
QC programs. 
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APPLICATION AVAILABLE KITS* COMPANY 
Allergy Testing Alternaria (Mold) (h), Bermuda Grass (h), Cat Dander (h), Egg 
White (h), Milk (h), Mite Pternoyssinus (h), Mountain Cedar (h), 
Short Ragweed (h), Timothy Grass (h), Wheat (food) (h)  
ImTech (h) 
Autoimmune ASCA (h), beta-2 Microglobulin (h,m), Centromere B (h), 
Chromatin (h), DNA (h),ENA Profile 4 (SSA, SSB, Sm, ENA Profile 
5 SSA, SSB, Sm, RNP, Scl-70) (h), ENA Profile 6 (SSA, SSB, Sm, 
RNP, Scl-70, Jo-1) (h), Gliadin A (h), Gliadin G (h), Histone (h), 
Histone H1 (h), Histone H2A (h), Histone H2B (h), Histone H3 (h), 
Histone H4 (h), HSP-27 pS82 (G), HSP-27 Total (G), HSP-32 (h), 
HSP-65 (h), HSP-71 (h), HSP-90 a (h), HSP-90 b (h), Jo-1 (h), PCNA 
(h,m), PR3 (h), PR3 (cANCA) (m), RF (h), Ribosomal P (h,m), RNP 
(h,m), RNP-A (h), RNP-C (h), SCF (h,m), Scl-70 (h,m), Serum 
Amyloid P (h), SLE Profile 8 (SSA, SSB, Sm, RNP, Scl-70, Jo-1, 
Ribosome-P, chromatin) (h), Sm (G) (h), Smith (h,m), SSA (h,m), 
SSB (h,m), Streptolysin O (h), TG (h),  
TPO (h,m), Transglutaminase A (h), Transglutaminase G (h)  
RBM(h,m) 
Cancer Markers Alpha Fetoprotein (h), Cancer Antigen 125 (h), Carcinoembryonic 
Antigen (h), PSA, Free (h) 
RBM(h) 
 
Cardiac Markers Creatine Kinase-MB (h), Endothelin-1 (m), PAP (h), SGOT (h,m), 
TIMP-1 (h,m) 
RBM(h,m) 
 
Cytokine Abeta 40 (h), Abeta 42 (h), BDNF (h), DR-5 (h), EGF (h,m), ENA-78 
(h), Eotaxin (h,m), Fatty Acid Binding Protein (h), FGF-basic (h,m), 
G-CSF (h,m), GCP-2 (m), GM-CSF (h,m,rt), GRO alpha (h), GRO-
KC (rt), HGF (h,m), I-TAC (h), ICAM-1 (h), IFN-alpha (h), IFN-
gamma (h,m,rt), IL-10 (h,m,rt), IL-11 (m), IL-12 (h,m), IL-12 p40 
(h,m), IL-12 p40/p70 (m) (rt), IL-12 p70 (h,m,rt), IL-13 (h,m), IL-15 
(h,m), IL-16 (h), IL-17 (h,m), IL-18 (rt), IL-1alpha (h,m,rt), IL-1beta 
(h,m,rt), IL-1ra (h), IL-1ra/IL-1F3 (h), IL-2 (h,m,rt), IL-3 (h,m), IL-4 
(h,m,rt), IL-5 (h,m,rt), IL-6 (h,m,rt), IL-7 (h,m), IL-8 (h), IL-9 (m), IP-
10 (h,m), JE/MCP-1 (m), KC (m), KC/GROa (m), LIF (m), IL-8 (h), 
IL-9 (m), IP-10 (h,m), JE/MCP-1 (m), KC (m), KC/GROa (m), LIF 
(m), MCP-3(h,m), MCP-5 (m) 
B-R(m); 
Bios (h,m,rt);  
Linco ( h,m,rt); 
RD(h,m); 
UP(h,m), RBM 
(h,m) 
Endocrine ACTH 
(h), Adiponectin 
(h,m), Amylin 
(m) (rt) (h), C-
Peptide (h), 
Calcitonin (h), 
CRF Linco 
ACTH (h), Adiponectin (h,m), Amylin (m) (rt) (h), C-Peptide (h), 
Calcitonin (h), CRF(h), FGF-9 (m), FSH (h), GH (h), GLP-1 (h,m,rt), 
Glucagon (m) (rt) (h), Growth Hormone (h,m), Insulin (h,m,rt), 
Leptin (h,m,rt), LH (h), Lipoprotein (a) (h), PAI-1(active) (h), PAI-1 
(total) (h,m), Prolactin (h), Resistin (h,m,rt), T3 (h), T4 (h), TBG (h), 
Thyroglobulin (h), TSH (h)  
Linco (h,m,rt);  
RBM ( h,m) 
Gene Expression IL6R(h), ACTB (h), BAD (h), BAK1 (BAK) (h), BCL2 (h), BCL2L1 
(BCL-XL) (h), CDKN1A (CDKN1) (h), CFLAR (CFLIP) (h), CSF2 
(h), GAPD (h), IFN-gamma (h), IL-1 beta (h), IL-10 (h), IL-2 (h), IL-6 
(h), IL-8 (h), NFKB2 (h), NFKBIA (NFKIA) (h), NKFB1 (h), PPIB 
(h), Ptk2B (RAFTK) (h), RELA (h), RELB (h), TNF (h), TNFAIP3 
(A20) (h), TNFRSF6 (FAS) (h), TNFSF6 (FASL) (h), VEGF (h)  
Bios (h); 
MBio (h) 
 
MMP MMP-1 (h), MMP-12 (h), MMP-13 (h), MMP-2 (h), MMP-3 (h), 
MMP-7 (h), MMP-8(h), MMP-9 (h) 
RD (h); Bios (h) 
Genotyping FlexMAP™ (G), Mitochondrial DNA Screening (h), Tag-It™ 
Mutation Detection Kit(G), Y-SNP Identification (h) 
Bio (h), Mira(h),  
TmBio (h) 
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APPLICATION AVAILABLE KITS* COMPANY 
Infectious 
Disease 
Adenovirus (h,m), Bordetella pertussis (h), Campylobacter jejuni 
(h), Chlamydia pneumoniae (h), Chlamydia trachomatis (h), 
Cholera Toxin (h), Cholera Toxin b (h), Clostridium piliforme 
(Tyzzer's) (m), Cytomegalovirus (h,m), Diphtheria Toxin (h), 
Ectromelia virus (m), EDIM (Epidemic diarrhea of infant mice) (m), 
Encephalitozoon cuniculi (m), Epstein-Barr EA (h), Epstein-Barr 
NA (h), Epstein-Barr VCA (h), HBV Core (h), HBV Envelope (h), 
HBV Surface (Ad) (h), HBV Surface (Ay) (h), HCV Core (h), HCV 
NS3 (h), HCV NS4 (h), HCV NS5 (h), Helicobacter pylori (h), 
Hepatitis A (h), Hepatitis D (h), HEV orf2 3KD (h), HEV orf2 6KD 
(h), HEV orf3 3KD (h), HIV-1 gp120 (h), HIV-1 gp41 (h), HIV-1 p24 
(h), HPV (h), HSV-1 gD (h), HSV-1/2 (h), HSV-2 gG (h), HTLV-1/2 
(h), Influenza A (h), Influenza A H3N2 (h), Influenza B (h), 
Leishmania donovani (h), Lyme disease (h), Lymphocytic 
choriomeningitis virus (m), M. pneumoniae (h), M. tuberculosis (h), 
Minute virus (m), Mumps (h), Mycoplasma pulmonis (m), 
Parainfluenza 1 (h), Parainfluenza 2 (h), Parainfluenza 3 (h), 
Parvovirus (m), Pneumonia virus of mice (m)  
RBM (h,m) 
Isotyping IgA (h,m), IgE (h,m), IgG1 (m), IgG2alpha (m), IgG2beta (m), IgG3 
(m), IgM (h,m), light chain (kappa or gamma) (m) 
UP (h,m);  
RBM(h,m) 
Metabolic 
Markers 
Apolipoprotein A-1 (m), Apolipoprotein A-I (h), Apolipoprotein 
A-II (h), Apolipoprotein B (h), Apolipoprotein C-II (h), 
Apolipoprotein C-III (h), Apolipoprotein E (h), beta-2 Glycoprotein 
(h,m), Collagen Type 1 (h), Collagen Type 2(h), Collagen Type 4 (h), 
Collagen Type 6 (h), Glutathione S-Transferase (h,m), 
Pancreatic Islet Cells (h), tTG (Celiac Disease) (h)  
RBM (h,m), 
Linco  
Tissue Typing HLA Class I and II (h), HLA Class I Single Antigen Antibody, 
Group 1 (h), HLA Class I Single Antigen Antibody, Group 2 (h), 
PRA Class I (h), PRA Class I and II (h), PRA Class II (h), SSO Class I 
HLA-A (h), SSO Class I HLA-B (h), SSO Class I HLA-C(h), SSO 
Class II DP (h), SSO Class II DQB1 (h), SSO Class II DRB1 (h), SSO 
Class II DRB3,4,5 (h)  
Lambda (h) 
Kinase 
Phosphorylated 
Protein 
Akt (G), Akt (Ser473) (G), Akt (total) (G), Akt/PKB (total) (G), 
Akt/PKBpS473 (G), ATF2 (Thr71) (G), ATF2 (total) (G), CREB 
(pS133) (G), CREB (Total) (G), Erk 1/2(pTpY185/187) (G), Erk 1/2 
(Total) (G), Erk-2 (G), Erk1 (Thr202/Tyr204) (G), Erk1/2 
(Thr202/Tyr204, Thr185/Tyr187) (G), Erk2 (Thr185/Tyr187) (G), 
Erk2 (total) (G),GSK 3beta (pS9) (G), GSK-3a/b (Ser21/Ser9) (G), 
GSK-3beta (G), IGF 1R  
UP (G), Bios (G) 
Transcription 
Factors-Nuclear 
Receptors 
AP-2 (G), CREB (G), EGR (h), HIF-1 (h), NF-1 (h), NFAT (h), NFkB 
Gene Family(h), PPAR (h), SRE (h), YY1 (h) 
Bios (h), MBio 
(h) 
* Human (h), mouse (m): rat (rt): general (G), ImmuneTech (ImTech); Rules Based Medicine (RBM); Bio-
Rad (B-R); BioSource (Bios); Linco Research (Linco); Qiagen; R&D Systems (RD); and Upstate Group 
(UP); Marligen Biosciences (MBio), MiraBio (Mira); Tm BioScience (TmBio); One Lambda (LAMBDA). 
Table 5. Aplication area and available kits 
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